Cargando…
What Should Be Done About Bias and Misconduct in Clinical Trials?
Autores principales: | Fairman, Kathleen A., Curtiss, Frederic R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437735/ https://www.ncbi.nlm.nih.gov/pubmed/19236130 http://dx.doi.org/10.18553/jmcp.2009.15.2.154 |
Ejemplares similares
-
What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011) -
Switching Antidepressant Drug Therapy Helps Some Patients Some of the Time--What TORDIA, STAR*D, and Observational Research Have Taught Us About Treatment-Resistant Depression
por: Curtiss, Frederic R., et al.
Publicado: (2008) -
Making the World Safe for Evidence-Based Policy: Let's Slay the Biases in Research on Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2008) -
VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
por: Fairman, Kathleen A., et al.
Publicado: (2012) -
Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?
por: Curtiss, Frederic R., et al.
Publicado: (2010)